Trials / Unknown
UnknownNCT05894421
TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQB2223 Injection Combined With Penpulimab Injection in Subjects With Advanced Cancers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB2223 is a recombinant, fully humanized antibody that binds lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. This is a phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and effectiveness of TQB2223 injection in combination with Penpulimab in subjects with advanced cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2223 injection+ Penpulimab Injection | TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody. |
Timeline
- Start date
- 2023-06-06
- Primary completion
- 2025-01-01
- Completion
- 2026-01-01
- First posted
- 2023-06-08
- Last updated
- 2024-03-12
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05894421. Inclusion in this directory is not an endorsement.